BRÈVE

sur EMD Electronics (isin : DE0006599905)

Merck KGaA Discontinues Phase III Trials of Xevinapant in Head & Neck Cancer

Graphique de l'évolution du cours de l'action EMD Electronics (EBR:MRK).

Merck KGaA announced the discontinuation of its Phase III clinical trials involving xevinapant for the treatment of locally advanced head and neck cancer. The decision affects two studies: TrilynX, which combined xevinapant with platinum-based chemotherapy, and X-Ray Vision, which combined xevinapant with radiotherapy.

The decision came after an interim analysis by the Independent Data Monitoring Committee. The analysis concluded that the trials were unlikely to meet the primary objective of prolonging event-free survival. With the data in hand, Merck KGaA deemed it reasonable to halt both studies.

Xevinapant is still under clinical investigation and not approved for any indication globally. The company has decided to halt further trials to focus on other research and development efforts.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de EMD Electronics